Compare Enbridge Inc (ENB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Enbridge Inc trades at $47.45 (market cap $105.42B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Enbridge Inc is far larger — about 21.6× Travere Therapeutics Inc. Common Stock's market cap, and Enbridge Inc pays a 5.9% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ENB | TVTX | |
|---|---|---|
Market Cap | $105.42B | $4.88B |
Volume | 3,621,007 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $58.04 | $67.52 |
52-Week Low | $45.23 | $26.79 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $187.30B | $5.01B |
Dividend Yield | 5.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $47.35, up 0.85% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with three consecutive quarterly earnings beats and a 6% dividend yield. Revenue grew to $65.19 billion in 2025 with net income of $7.49 billion, though 2026 projections show margin compression. Recent news highlights ENB's expansion into European renewables and Permian Basin acquisitions as growth drivers.
ENB offers income investors a stable 6% yield with growth potential from its $41 billion project backlog, but faces headwinds from rising interest rates and potential oil price volatility. Analyst consensus is balanced with 48% buy ratings and a $61.63 price target suggesting 30% upside, though technical indicators remain cautious near-term.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
